0558712 20250224111103.420220630235959.9 85140144811 000805341600001 10.1093/infdis/jiac161 6 s. P cav_un_epca*02538270022-18992268 (2022)1385-1390Oxford University Press COVID-19 postinfection immunity vaccine effectiveness SARS-CoV-2 Omicron variant hospitalization cav_un_auth*0101206 Šmíd Martin UTIA-B Ekonometrie Department of Econometrics E E Department of Econometrics Ústav teorie informace a automatizace AV ČR, v. v. i. cav_un_auth*1103974 Berec Luděk BC-A ENTU - Ekologie Ecology Insect Ecology Biologické centrum AV ČR, v. v. i. cav_un_auth*0318938 Přibylová L. CZ cav_un_auth*0265570 Májek O. CZ cav_un_auth*0022185 Pavlík T. CZ cav_un_auth*0015207 Jarkovský J. CZ cav_un_auth*0430306 Weiner Jakub UTIA-B Ekonometrie Department of Econometrics E E CZ Ústav teorie informace a automatizace AV ČR, v. v. i. cav_un_auth*0431344 Barusová Tamara UIVT-O Oddělení statistického modelování Department of Statistical Modelling SK Ústav informatiky AV ČR, v. v. i. cav_un_auth*0091778 Trnka J. CZ http://library.utia.cas.cz/separaty/2022/E/smid-0558712.pdf https://doi.org/10.1093/infdis/jiac161 The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evades immunity conferred by vaccines and previous infections. We used a Cox proportional hazards model and a logistic regression on individual-level population-wide data from the Czech Republic to estimate risks of infection and hospitalization, including severe states. A recent (≤2 months) full vaccination reached vaccine effectiveness (VE) of 43% (95% confidence interval [CI], 42%–44%) against infection by Omicron compared to 73% (95% CI, 72%–74%) against Delta. A recent booster increased VE to 56% (95% CI, 55%–56%) against Omicron infection compared to 90% (95% CI, 90%–91%) for Delta. The VE against Omicron hospitalization of a recent full vaccination was 45% (95% 95% CI, 29%–57%), with a recent booster 87% (95% CI, 84%–88%). The VE against the need for oxygen therapy due to Omicron was 57% (95% CI, 32%–72%) for recent vaccination, 90% (95% CI, 87%–92%) for a recent booster. Postinfection protection against Omicron hospitalization declined from 68% (95% CI, 68%–69%) at ≤6 months to 13% (95% CI, 11%–14%) at >6 months after a previous infection. The odds ratios for Omicron relative to Delta were 0.36 (95% CI, .34–.38) for hospitalization, 0.24 (95% CI, .22–.26) for oxygen, and 0.24 (95% CI, .21–.28) for intensive care unit admission. Recent vaccination still brings substantial protection against severe outcome for Omicron. WOS IN 10000 10200 10201 2023 9 BC-A 30000 30100 30102 UIVT-O 10000 10100 10103 4 A 4a 20250224111103.4 BC-A FN RVO:67985556 RVO:67985807 RVO:60077344 http://hdl.handle.net/11104/0332277 S 1* Article Immunology|Infectious Diseases|Microbiology A INFECTIOUSDISEASES|MICROBIOLOGY|IMMUNOLOGY 5.4 2.7 9.5 0.05666 2.208 49684 2.386 6.200 539 Q1 79 Q1 Q1* 1.34 Q1 82.6 2022 Soubory v repozitáři: 558712.pdf 85140144811 SCOPUS 35482442 PUBMED 000805341600001 WOS cav_un_epca*0253827 Journal of Infectious Diseases 0022-1899 1537-6613 Roč. 226 č. 8 2022 1385 1390 Oxford University Press